Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658073 | 0.87 | TRPV1 (0.41) | TRPV1CCR4ROCK1NR2F2RAB9A | |
| SCHEMBL6624139 | 0.85 | TRPV1 (0.44) | TRPV1ROCK1PDK1 | |
| SCHEMBL6625347 | 0.83 | TRPV1 (0.53) | TRPV1ROCK1 | |
| SCHEMBL5658596 | 0.82 | TRPV1 (0.38) | TRPV1LMNACCR4ROCK1SLC22A12 | |
| SCHEMBL27642766 | 0.82 | TRPV1 (0.43) | TRPV1LMNAALDH1A1ROCK1F2 | |
| SCHEMBL5659704 | 0.82 | TRPV1 (0.40) | TRPV1ROCK1NR2F2RAB9ASLC22A12 | |
| SCHEMBL27663639 | 0.78 | ROS1 (0.39) | TRPV1LMNAALDH1A1ROCK1NR2F2 | |
| SCHEMBL5431368 | 0.77 | ROS1 (0.51) | TRPV1LMNAALDH1A1ROCK1NR2F2 | |
| SCHEMBL27663669 | 0.77 | TRPV1 (0.44) | TRPV1ROCK1 | |
| SCHEMBL27642770 | 0.77 | TRPV1 (0.46) | TRPV1ALDH1A1ROCK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | L3MBTL1 4408/4885TRPV1 37/4885LMNA 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.